articleNew England Journal of MedicineMar 21, 2023Closed access

Hydrocortisone in Severe Community-Acquired Pneumonia

Université de Tours · Inserm · +35 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

Background

Whether the antiinflammatory and immunomodulatory effects of glucocorticoids may decrease mortality among patients with severe community-acquired pneumonia is unclear.

Methods

In this phase 3, multicenter, double-blind, randomized, controlled trial, we assigned adults who had been admitted to the intensive care unit (ICU) for severe community-acquired pneumonia to receive intravenous hydrocortisone (200 mg daily for either 4 or 7 days as determined by clinical improvement, followed by tapering for a total of 8 or 14 days) or to receive placebo. All the patients received standard therapy, including antibiotics and supportive care. The primary outcome was death at 28 days.

Citation impact

423
total citations
FWCI
77.03
Percentile
100%
References
32
Citations per year

Authors

38

Topics & keywords

Keywords
  • Medicine
  • Placebo
  • Confidence interval
  • Intensive care unit
  • Randomization
  • Mechanical ventilation
  • Pneumonia
  • Randomized controlled trial
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding